Akshay Krishnadas Vaishnaw
President of R&D, Member of Scientific Advisory Board and DirectorDr. Akshay Krishnadas Vaishnaw, M.D. Ph.D. is Director of Hemab ApS from January 2024. He served as Chief Innovation Officer at Alnylam Pharmaceuticals, Inc. since October 02, 2023 until May 2025 and served as its Member of the Scientific Advisory Board until May 2025. He has been an Independent Director at Hemab Therapeutics Holdings, Inc. since January 2024. He is Venture Partner at Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). since 2024. He had been President at Alnylam Pharmaceuticals, Inc. since January 01, 2022 until October 02, 2023 and served as its President of Research and Development since March 2018 until January 2022 and was its Executive Vice President of Research and Development from December 2014 to March 2018. Dr. Vaishnaw served as Chief Medical Officer of Alnylam Pharmaceuticals, Inc. since June 13, 2011 until December 2016. He serves as Member of Scientific Advisory Board at Scholar Rock Holding Corp since 2014 and is its Director since May 21, 2019 and has been its President of R&D since April 2025. He served as Executive Vice President of Alnylam Pharmaceuticals, Inc. from June 2012 to December 2014. He served as Senior Vice President of Clinical Research at Alnylam Pharmaceuticals, Inc. from December 2008 to June 13, 2011 and served as its Senior Vice President from June 13, 2011 to June 27, 2012. Previously, he served as a Vice President of Clinical Research of Alnylam Pharmaceuticals Inc. from February 7, 2006 to January 27, 2009. At Alnylam, he was responsible for leading and managing Alnylam Pharmaceuticals Inc.'s clinical organization. Dr. Vaishnaw joined Alnylam in February 2006 from Biogen Idec, where he served as Senior Director for Translational Medicine. From December 1998 to December 2005, he held various positions at Biogen Inc (Prior to 2006, he was at Biogen as Senior Director, Translational Medicine). and was involved in many aspects of clinical research and business development and led the effort for the approval of alefacept (Amevive(TM)) for psoriasis. Dr. Vaishnaw has extensive clinical experience in the industry as well as in the academic and hospital settings. Dr. Vaishnaw's other responsibilities at Biogen Idec included initiating a cross-organizational effort in Translational Medicine across all phases of development and multiple therapeutic areas, participating on M&A activity. He was an Independent Director of Editas Medicine, Inc. since July 29, 2016 until June 30, 2024 and served at Visterra, Inc. from October 31, 2014 until 2018. He has been a Member of Scientific Advisory Board at Scholar Rock, Inc. since September 2014. In addition, he has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease. He is a Fellow of the Royal College of Physicians, UK and received an Executive M.B.A. from Harvard Business School. Dr. Vaishnaw received his M.D. from the University of Wales College of Medicine, UK, with Distinctions in Pathology and Medicine and his Ph.D. from the University of London, UK, in Molecular Immunology. Dr. Vaishnaw holds an MBBCh from Cardiff University School of Medicine (formerly, the University of Wales College of Medicine, U.K.).
Positions
- Company NameScholar Rock Holding CorporationStock CodeSRRKPositionPresident of R&D, Member of Scientific Advisory Board and DirectorColleagues
- DLDavid L. HallalCEO & Chairman of the Board
- VSVikas SinhaCFO & Treasurer
- RKRobert Keith WoodsChief Operating Officer
- AKAkshay Krishnadas VaishnawPresident of R&D, Member of Scientific Advisory Board and Director
- EMErin MooreInterim Principal Financial & Accounting Officer
- KMKristina M. BurowIndependent Director
- JSJeffrey S. FlierIndependent Director & Member of Scientific Advisory Board
- JRJoshua ReedIndependent Director
- Company NameHemab Therapeutics Holdings, Inc.Stock CodeCOAGPositionIndependent DirectorColleagues
- BSBenny SorensenPresident, CEO & Director
- JMJohn Michael MaraganoreIndependent Chairman
- MNMads Nikolaj Behrndt-EriksenCFO & GM
- CECatherine Eilleen MadiganChief Medical Officer
- ASAnanthram Sreenivasa MurthyChief Operating Officer
- KWKaren WeisbachChief People & Culture Officer
- LCLinda Cathavina BainIndependent Director
- KWKeli WalbertDirector
